{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:58:31Z","timestamp":1757624311130,"version":"3.44.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cellular Immunotherapies have transformed therapeutic options for individuals with hematologic malignancies over the past 10 years. There are several distinct types of cellular immunotherapies, each with potential applications to CNS cancers. Here, we review cancer cellular therapeutics for cancers of the brain and spinal cord, focusing on the preclinical and clinical studies that have been done in glioblastoma, diffuse intrinsic pontine glioma\/diffuse midline glioma, medulloblastoma and lymphoma involving the central nervous system. Numerous potential therapeutic targets have been identified, and several early clinical trials have demonstrated safety and feasibility of administering CAR T and CAR NK cells for intracranial tumors. Addressing mechanisms of treatment failure, while safely and effectively studying the most promising therapies will advance the treatment landscape for these extremely challenging diseases.<\/jats:p>","DOI":"10.1093\/noajnl\/vdaf120","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:35:21Z","timestamp":1757421321000},"page":"iv84-iv94","source":"Crossref","is-referenced-by-count":0,"title":["Cellular immunotherapies for central nervous system cancers"],"prefix":"10.1093","volume":"7","author":[{"given":"Brian J","family":"Scott","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford University , Stanford, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3547-237X","authenticated-orcid":false,"given":"Michelle","family":"Monje","sequence":"additional","affiliation":[{"name":"Howard Hughes Medical Institute, Stanford University , Stanford, CA ,","place":["USA"]},{"name":"Department of Neurology and Neurological Sciences, Stanford University , Stanford, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"4","key":"2025090908351827900_CIT0001","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol."},{"issue":"1","key":"2025090908351827900_CIT0002","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci Rep."},{"issue":"23","key":"2025090908351827900_CIT0003","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med."},{"issue":"2","key":"2025090908351827900_CIT0004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","article-title":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","volume":"22","author":"Braendstrup","year":"2020","journal-title":"Cytotherapy."},{"issue":"6","key":"2025090908351827900_CIT0005","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"26","key":"2025090908351827900_CIT0006","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"24","key":"2025090908351827900_CIT0007","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol."},{"issue":"Supplement_5","key":"2025090908351827900_CIT0008","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"3","key":"2025090908351827900_CIT0009","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/neuonc\/noac217","article-title":"Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000\u20132014 (CONCORD-3)","volume":"25","author":"Girardi","year":"2023","journal-title":"Neuro-Oncology."},{"issue":"28","key":"2025090908351827900_CIT0010","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol."},{"issue":"4","key":"2025090908351827900_CIT0011","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"14","key":"2025090908351827900_CIT0012","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer."},{"issue":"23","key":"2025090908351827900_CIT0013","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"issue":"4","key":"2025090908351827900_CIT0014","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","article-title":"Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2025090908351827900_CIT0015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/neuonc\/nox208","article-title":"Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"20","author":"Omuro","year":"2018","journal-title":"Neuro-Oncology."},{"issue":"1","key":"2025090908351827900_CIT0016","first-page":"vdae025","article-title":"Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: literature review and future directions","volume":"6","author":"Goutnik","year":"2024","journal-title":"Neurooncol. Adv."},{"issue":"18","key":"2025090908351827900_CIT0017","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"26","key":"2025090908351827900_CIT0018","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med."},{"issue":"8","key":"2025090908351827900_CIT0019","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"4","key":"2025090908351827900_CIT0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med."},{"issue":"2","key":"2025090908351827900_CIT0021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/neuonc\/noab182","article-title":"Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice","volume":"24","author":"Chuntova","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"1","key":"2025090908351827900_CIT0022","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat Commun."},{"issue":"3","key":"2025090908351827900_CIT0023","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat Cancer"},{"issue":"1","key":"2025090908351827900_CIT0024","first-page":"vdac185","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neurooncol. Adv."},{"issue":"5","key":"2025090908351827900_CIT0025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med."},{"issue":"14","key":"2025090908351827900_CIT0026","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med."},{"issue":"14","key":"2025090908351827900_CIT0027","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMe2401307","article-title":"CAR T-cell therapy for glioblastoma. Phimister EG, ed","volume":"390","author":"Jenkins","year":"2024","journal-title":"N Engl J Med."},{"issue":"3","key":"2025090908351827900_CIT0028","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41435-024-00275-6","article-title":"HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo","volume":"25","author":"Li","year":"2024","journal-title":"Genes Immun."},{"issue":"8","key":"2025090908351827900_CIT0029","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor\u2013modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"2025090908351827900_CIT0030","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro-Oncology."},{"key":"2025090908351827900_CIT0031","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a Novel CAR-T therapeutic target for glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol Ther Oncolytics."},{"issue":"8","key":"2025090908351827900_CIT0032","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"14","key":"2025090908351827900_CIT0033","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2025090908351827900_CIT0034","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2025090908351827900_CIT0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","article-title":"Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2025090908351827900_CIT0036","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","article-title":"Contemporary survival endpoints: an international diffuse intrinsic pontine glioma registry study","volume":"19","author":"Cooney","year":"2017","journal-title":"Neuro-Oncology."},{"issue":"4","key":"2025090908351827900_CIT0037","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"2025090908351827900_CIT0038","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2019.03.009","article-title":"Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review","volume":"4","author":"Gallitto","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"Supplement_2","key":"2025090908351827900_CIT0039","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/neuonc\/noad220","article-title":"H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions","volume":"26","author":"Van Den Bent","year":"2024","journal-title":"Neuro-Oncology."},{"issue":"9","key":"2025090908351827900_CIT0040","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","article-title":"The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies","volume":"24","author":"Persson","year":"2022","journal-title":"Neuro-Oncology."},{"key":"2025090908351827900_CIT0041","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol."},{"issue":"5","key":"2025090908351827900_CIT0042","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat Med."},{"issue":"7903","key":"2025090908351827900_CIT0043","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature."},{"issue":"4","key":"2025090908351827900_CIT0044","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med."},{"issue":"8046","key":"2025090908351827900_CIT0045","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature."},{"issue":"23","key":"2025090908351827900_CIT0046","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I Trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol."},{"issue":"1","key":"2025090908351827900_CIT0047","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"key":"2025090908351827900_CIT0048","first-page":"1544","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume-title":"Nat Med.","author":"Vitanza","year":"2021"},{"issue":"6","key":"2025090908351827900_CIT0049","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","article-title":"Risk stratification of childhood medulloblastoma in the molecular era: the current consensus","volume":"131","author":"Ramaswamy","year":"2016","journal-title":"Acta Neuropathol (Berl)."},{"key":"2025090908351827900_CIT0050","volume-title":"Central nervous system tumors","author":"WHO Classification of Tumors Editorial Board","year":"2021","edition":"5"},{"key":"2025090908351827900_CIT0051","doi-asserted-by":"crossref","first-page":"100861","DOI":"10.1016\/j.neo.2022.100861","article-title":"Current studies and future directions for medulloblastoma: a review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group","volume":"35","author":"Cooney","year":"2023","journal-title":"Neoplasia"},{"issue":"5","key":"2025090908351827900_CIT0052","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med."},{"issue":"1","key":"2025090908351827900_CIT0053","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells","volume":"6","author":"Nellan","year":"2018","journal-title":"J ImmunoTher Cancer."},{"issue":"9","key":"2025090908351827900_CIT0054","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med."},{"issue":"1","key":"2025090908351827900_CIT0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"2025090908351827900_CIT0056","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","article-title":"GD2-Targeting CAR T-cell therapy for patients with GD2+ medulloblastoma","volume":"30","author":"Ciccone","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2025090908351827900_CIT0057","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2025090908351827900_CIT0058","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clml.2022.09.008","article-title":"Chimeric antigen receptor T-Cell (CAR T-Cell) therapy for primary and secondary central nervous system lymphoma: a systematic review of literature","volume":"23","author":"Asghar","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025090908351827900_CIT0059","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv."},{"issue":"4","key":"2025090908351827900_CIT0060","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/j.clml.2023.12.012","article-title":"Chimeric antigen receptor T - cell therapy for large B-cell lymphoma patients with central nervous system involvement, a systematic review and meta-analysis","volume":"24","author":"Elgohary","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2025090908351827900_CIT0061","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/ajh.27316","article-title":"CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network","volume":"99","author":"Choquet","year":"2024","journal-title":"Am J Hematol."},{"issue":"15","key":"2025090908351827900_CIT0062","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood."},{"issue":"10","key":"2025090908351827900_CIT0063","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.3390\/cancers13102503","article-title":"CAR T-Cells for CNS lymphoma: driving into new terrain","volume":"13","author":"Karschnia","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"2025090908351827900_CIT0064","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/cancers17030462","article-title":"Immune resistance in glioblastoma: understanding the barriers to ICI and CAR-T cell therapy","volume":"17","author":"Eckert","year":"2025","journal-title":"Cancers"},{"issue":"6","key":"2025090908351827900_CIT0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"key":"2025090908351827900_CIT0066","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics."},{"issue":"7","key":"2025090908351827900_CIT0067","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","article-title":"Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant","volume":"24","author":"De Billy","year":"2022","journal-title":"Neuro-Oncology."},{"issue":"3","key":"2025090908351827900_CIT0068","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"2025090908351827900_CIT0069","doi-asserted-by":"crossref","first-page":"640082","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T Cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front Immunol."},{"issue":"7965","key":"2025090908351827900_CIT0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41586-023-05968-y","article-title":"The neuroscience of cancer","volume":"618","author":"Mancusi","year":"2023","journal-title":"Nature."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/Supplement_4\/iv84\/64229924\/vdaf120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/Supplement_4\/iv84\/64229924\/vdaf120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:35:30Z","timestamp":1757421330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/7\/Supplement_4\/iv84\/8249865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":70,"journal-issue":{"issue":"Supplement_4","published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf120","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,9]]}}}